Industry
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
Failure Rate
50.0%
1 terminated/withdrawn out of 2 trials
Success Rate
0.0%
-86.5% vs industry average
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed trials have results
Key Signals
1 with results
Enrollment Performance
Analytics
Phase 3
1(50.0%)
Phase 1
1(50.0%)
2Total
Phase 3(1)
Phase 1(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (2)
Showing 2 of 2 trials
NCT04647526Phase 3Active Not Recruiting
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
Role: lead
NCT05432193Phase 1Terminated
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Role: lead
All 2 trials loaded